New Data, New Drugs, and...a Vitamin for MS?
Stephen Krieger, MD, sits down with Bruce Cree to discuss multiple sclerosis (MS) highlights from the 67th Annual American Academy of Neurology meeting in Washington, DC. "This was a great meeting. We heard a lot of results from research in MS that will be important for us over the coming years," says Dr. Krieger, "For example, we heard the daclizumab clinical trial results. This was a phase 3 trial, a direct comparison with weekly intramuscular interferon injection. Daclizumab is a new candidate medicine for MS, with a new mechanism of action. It was superior to interferon in preventing relapses, preventing MRI lesions, and even preventing the accumulation of disability. It was positive on all three of those metrics."
-Dr. Stephen Krieger, Associate Professor, Neurology, Icahn School of Medicine, Attending, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, The Mount Sinai Hospital